- In October 2024, Carl Zeiss Microscopy, LLC, announced a partnership with Ultivue Inc. to co-market Ultivue's multiplex biomarker assays for tissue phenotyping, which will be integrated with the ZEISS Axioscan whole slide imaging system for data acquisition and analysis. This collaboration aims to provide a comprehensive solution for tissue preparation, image acquisition, and analysis, benefiting researchers in cancer biology, immunology, drug development, and various sectors including academia, biotech, pharma, and CROs
- In September 2024, Lunaphore, a Swiss life sciences firm specializing in technology for spatial biology, and Nucleai, a pioneer in AI-driven spatial biology for precision medicine, revealed a collaboration focused on enhancing the discovery of novel biomarkers and drug targets. This partnership will leverage advanced spatial imaging and machine learning technologies to unlock valuable insights from pathology data
- In May 2024, Illumina Inc. announced that it would present part of its latest research at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place in Chicago from May 31 to June 4. The presentations will feature data from several studies conducted in partnership with Labcorp, highlighting evidence that supports the use of comprehensive genomic profiling (CGP) over single gene testing (SGT). Additionally, Illumina will present the latest findings related to its molecular residual disease (MRD) assay, which is currently in development alongside major collaborators. A total of 14 abstracts from Illumina were accepted for the conference
- In April 2024, Merck announced its plan to acquire Mirus Bio for USD 600 million. Based in Madison, Wisconsin, Mirus Bio specializes in developing and selling transfection reagents. These reagents, including Mirus Bio's TransIT-VirusGEN®, facilitate the entry of genetic material into cells, playing a crucial role in the creation of viral vectors for cell and gene therapies
- In April 2021, Abcam, formerly known as QIAGEN (Suzhou) Translational Medicine Co., Ltd., announced an expansion of its strategic partnership aimed at developing and commercializing essential companion and in vitro diagnostic kits. This collaboration is focused on empowering MEDx to provide advanced diagnostic solutions in the Chinese market, underscoring both organizations' commitment to advancing precision medicine and improving diagnostic capabilities to meet healthcare needs in China
